<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254005</url>
  </required_header>
  <id_info>
    <org_study_id>1191.1</org_study_id>
    <nct_id>NCT02254005</nct_id>
  </id_info>
  <brief_title>Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer</brief_title>
  <official_title>An Open Phase I Single Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously in Female Patients With CD44v6 Positive Metastatic Breast Cancer With Repeated Administration in Patients With Clinical Benefit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of bivatuzumab mertansine</measure>
    <time_frame>up to day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant findings in laboratory tests</measure>
    <time_frame>up to day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant findings in vital signs</measure>
    <time_frame>up to day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>up to 1 year</time_frame>
    <description>assessed by response evaluation criteria in solid tumours (RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of bivatuzumab mertansine</measure>
    <time_frame>up to day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of CD44v6 recognising IgG antibodies (anti-CD44v6-IgG)</measure>
    <time_frame>up to day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with development of human anti-human antibodies (HAHA)</measure>
    <time_frame>up to day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>single dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bivatuzumab mertansine</intervention_name>
    <arm_group_label>single dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. female patients aged 18 years or older

          2. patients with breast cancer positive for CD44v6 in at least 50 % of the tumour cells

          3. patients with metastases pretreated with anthracyclines and taxanes (unless
             contraindications to taxanes and / or anthracyclines) or not amenable to established
             treatments

          4. measurable tumour deposits by one or more radiological techniques (MRI, CT)

          5. life expectancy of at least 6 months

          6. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2

          7. patients must have given written informed consent (which must be consistent with
             International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local
             legislation)

        Exclusion Criteria:

          1. hypersensitivity to humanised or murine antibodies, immunoconjugates or the excipients
             of the trial drugs

          2. known secondary malignancy requiring therapy

          3. active infectious disease

          4. brain metastases requiring therapy

          5. neuropathy common toxicity criteria (CTC) grade 2 or above

          6. absolute neutrophil count less than 1,500/mm3

          7. platelet count less than 100,000/mm3

          8. bilirubin greater than 1.5 mg/dl (&gt; 26 μmol/L, système internationale (SI) unit
             equivalent)

          9. aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than
             3 times the upper limit of normal

         10. serum creatinine greater than 1.5 mg/dl (&gt; 132 μmol/L, SI unit equivalent)

         11. concomitant non-oncological diseases which are considered relevant for the evaluation
             of the safety of the trial drug

         12. chemo- or immunotherapy within the past four weeks prior to treatment with the trial
             drug or during the trial (except for present trial drug)

         13. radiotherapy to breast and thorax region within the past four weeks before inclusion
             or during the trial

         14. women who are sexually active and unwilling to use a medically acceptable method of
             contraception

         15. pregnancy or lactation

         16. treatment with other investigational drugs or participation in another clinical trial
             within the past four weeks before start of therapy or concomitantly with this trial
             (except for present trial drug)

         17. patients unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

